Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) Director Lynn A. Tetrault sold 4,300 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $50.01, for a total transaction of $215,043.00. Following the transaction, the director now owns 3,000 shares in the company, valued at $150,030. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Rhythm Pharmaceuticals Stock Up 2.6 %
Shares of NASDAQ RYTM opened at $47.29 on Friday. Rhythm Pharmaceuticals, Inc. has a twelve month low of $20.97 and a twelve month high of $53.92. The stock has a market cap of $2.88 billion, a price-to-earnings ratio of -10.21 and a beta of 2.04. The company’s fifty day moving average is $46.05 and its 200-day moving average is $42.82.
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.16. Rhythm Pharmaceuticals had a negative return on equity of 221.65% and a negative net margin of 254.88%. The firm had revenue of $29.08 million for the quarter, compared to analyst estimates of $28.79 million. During the same period in the previous year, the company posted ($0.82) earnings per share. The company’s revenue for the quarter was up 51.3% on a year-over-year basis. On average, research analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -4.4 EPS for the current fiscal year.
Analyst Ratings Changes
Check Out Our Latest Research Report on RYTM
Hedge Funds Weigh In On Rhythm Pharmaceuticals
Several institutional investors and hedge funds have recently modified their holdings of the business. CWM LLC lifted its stake in Rhythm Pharmaceuticals by 62.6% in the second quarter. CWM LLC now owns 657 shares of the company’s stock valued at $27,000 after buying an additional 253 shares in the last quarter. AJOVista LLC bought a new stake in Rhythm Pharmaceuticals in the 4th quarter valued at $42,000. ORG Partners LLC acquired a new position in Rhythm Pharmaceuticals in the 2nd quarter worth $51,000. Quarry LP bought a new position in Rhythm Pharmaceuticals during the 4th quarter worth about $69,000. Finally, Quest Partners LLC raised its stake in shares of Rhythm Pharmaceuticals by 513.3% in the 2nd quarter. Quest Partners LLC now owns 1,662 shares of the company’s stock valued at $68,000 after purchasing an additional 1,391 shares during the period.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
Further Reading
- Five stocks we like better than Rhythm Pharmaceuticals
- How to buy stock: A step-by-step guide for beginners
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- Energy and Oil Stocks Explained
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- 3 Monster Growth Stocks to Buy Now
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.